行情

VRTX

VRTX

福泰制药
NASDAQ

实时行情|Nasdaq Last Sale

183.41
-0.20
-0.11%
盘后: 183.41 0 0.00% 16:46 09/27 EDT
开盘
183.20
昨收
183.61
最高
184.00
最低
181.45
成交量
146.94万
成交额
--
52周最高
280.99
52周最低
181.45
市值
475.82亿
市盈率(TTM)
24.17
分时
5日
1月
3月
1年
5年
直接作用抗病毒药物市场:2029 年全球需求分析和机会展望,其中详细概述了全球直接作用抗病毒药物市场
Research Nester released a report titled which delivers detailed overview of the global direct-acting antiviral medicines market in terms of market segmentation by drug class type, end-user and region.
AmericaNewsHour · 3小时前
Dare (DARE) 开始研究治疗外阴和阴道萎缩
Zacks.com · 3天前
Zacks 分析师博客亮点:迪士尼、Adobe、富国银行、IHS Markit 和 Vertex Pharma
Zacks.com · 3天前
Zacks 价值投资者亮点:如新企业、VF Corp、Yamana Gold、Meritor 和 Vertex Pharmaceuticals
Zacks Value Investor Highlights: Nu Skin Enterprises, VF Corp, Yamana Gold, Meritor and Vertex Pharmaceuticals
Zacks · 3天前
Vertex Pharmaceuticals (VRTX) 收益但滞后于市场:您应该知道的
Vertex Pharmaceuticals (VRTX) closed at $185.09 in the latest trading session, marking a +0.44% move from the prior day.
Zacks · 3天前
5 只目前在售的顶级股票
These stocks are disconnected from their earnings outlook as the analysts remain bullish but the Street is bearish.
Zacks · 4天前
Vertex Pharmaceuticals (VRTX) 是明智的长期购买吗?
Artisan Partners, a high value-added investment management firm, published its “Artisan Value Fund” second quarter 2021 investor letter – a copy of which can be downloaded here. A return of 7.77% was recorded by its Investor Class: ARTLX, 7.81% by its Advi...
Insider Monkey · 4天前
VRTX 与 PRTA:投资者现在应该购买哪只股票?
VRTX vs. PRTA: Which Stock Is the Better Value Option?
Zacks · 4天前
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解VRTX最新的财务预测,通过VRTX每股收益,每股净资产,每股现金流等数据分析福泰制药近期的经营情况,然后做出明智的投资选择。
分析师评级

26位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测VRTX价格均价为258.59,最高价位331.00,最低价为175.00。
EPS
机构持股
总机构数: 1,266
机构持股: 2.50亿
持股比例: 96.31%
总股本: 2.59亿
类型机构数股数
增持
382
1,980.35万
建仓
110
333.92万
减持
331
2,276.67万
平仓
124
162.57万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-1.09%
制药与医学研究
-0.90%
高管信息
Chairman/Executive Director
Jeffrey Leiden
President/Chief Executive Officer/Director
Reshma Kewalramani
Chief Financial Officer/Executive Vice President
Charles Wagner
Chief Operating Officer/Executive Vice President
Stuart Arbuckle
Executive Vice President/Chief Administrative Officer
Michael Parini
Executive Vice President/Chief Scientific Officer
David Altshuler
Executive Vice President
Carmen Bozic
Executive Vice President
Amit Sachdev
Executive Vice President
Bastiano Sanna
Executive Vice President
Ourania Tatsis
Senior Vice President/Chief Accounting Officer
Paul Silva
Lead Director/Independent Director
Bruce Sachs
Independent Director
Sangeeta Bhatia
Independent Director
Lloyd Carney
Independent Director
Alan Garber
Independent Director
Terrence Kearney
Independent Director
Yuchun Lee
Independent Director
Margaret Mcglynn
Independent Director
Diana McKenzie
暂无数据
VRTX 简况
Vertex Pharmaceuticals Inc是一家生物技术公司。该公司专注于囊性纤维化(CF)疗法的开发和商业化,并推进其在其他适应症的研发计划。该公司的上市药物为TRIKAFTA/KAFTRIO、SYMDEKO/SYMKEVI、ORKAMBI和KALYDECO。该公司提供的产品用于治疗囊性纤维化跨膜电导调节(CFTR)基因特异突变的CF患者。其lumacaftor、tezacaftor和elexacaftor等CFTR校正剂可帮助CFTR蛋白到达细胞表面。该公司为其他严重疾病提供小分子药物管道,在这些疾病中,它深入了解人类生物学的因果关系,包括疼痛、α-1抗胰蛋白酶缺乏症和APOL1介导的肾脏疾病。

微牛提供Vertex Pharmaceuticals Incorporated(NASDAQ-VRTX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的VRTX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易VRTX股票基本功能。